Login / Signup

A patent review of EZH2 inhibitors from 2017 and beyond.

Guoquan WanHuan FengChang SuYongxia ZhuLidan ZhangQiangsheng ZhangLuo-Ting Yu
Published in: Expert opinion on therapeutic patents (2023)
In recent years, a great number of structurally diverse EZH2 inhibitors have been identified, including EZH2 reversible inhibitors, EZH2 irreversible inhibitors, EZH2-based dual inhibitors and EZH2 degraders. Despite the multiple challenges, EZH2 inhibitors offer promising potential for the treatment of various diseases, such as cancers.
Keyphrases
  • long noncoding rna
  • long non coding rna
  • young adults
  • climate change